title: Effects of postmenopausal hormone therapy every day and every other day on lipid levels according to difference in body mass index.
abstract: OBJECTIVE
  The objective of this study was to determine the effects of postmenopausal estrogen and progestogen therapy (EPT) every day and every other day on lipid levels, particularly triglyceride (TG) levels, according to difference in body mass index (BMI).
  
  
  METHODS
  Ninety-nine postmenopausal women (mean age, 53.9 +/- 5.6 years; mean BMI, 22.8 +/- 2.8 kg/m) were randomly treated with EPT every other day or every day for 1 year. Fifty women received oral administration of 0.625 mg of conjugated equine estrogen (CEE) and 2.5 mg of medroxyprogesterone acetate (MPA) every other day, and 49 women received oral administration of 0.625 mg of CEE and 2.5 mg of MPA every day. Blood samples were collected at baseline and after 1 year of therapy for measurement of fasting TG, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), and apolipoproteins. Data from 88 of the 99 postmenopausal women were used for analysis.
  
  
  RESULTS
  In women whose BMI was 25 kg/m or higher, TG levels during EPT every day increased by 26.8%, while TG levels during EPT every other day decreased by 12.3%. There was a significant (P < 0.05) difference between percentage changes in TG during EPT every day and every other day. In women whose BMI was less than 25 kg/m, TG levels during EPT every day increased by 21.7%, while during EPT every other day TG levels did not change. The mean levels of estradiol during EPT every day in women whose BMI was less than 25 kg/m and in women whose BMI was 25 kg/m or higher were 28.5 and 38.7 pg/mL, respectively, the difference between these levels was significant (P < 0.01). On the other hand, there was no significant difference between levels of estradiol during EPT every other day in these two BMI groups.
  
  
  CONCLUSIONS
  Triglyceride levels during EPT every day with conventional doses of CEE and MPA increased more in overweight and obese postmenopausal women in association with increased estrogen levels.
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine, University of Tokushima, Tokushima, Japan. yasui@clin.med.tokushima-u.ac.jp
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Yasui
authors.forename: Yuka
authors.initials: Y
authors.lastname: Umino
authors.forename: Masaya
authors.initials: M
authors.lastname: Takikawa
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Uemura
authors.forename: Akira
authors.initials: A
authors.lastname: Kuwahara
authors.forename: Toshiya
authors.initials: T
authors.lastname: Matsuzaki
authors.forename: Masahiko
authors.initials: M
authors.lastname: Maegawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Furumoto
authors.forename: Masakazu
authors.initials: M
authors.lastname: Miura
authors.forename: Minoru
authors.initials: M
authors.lastname: Irahara
mesh_terms: D000284:Administration, Oral; D001053:Apolipoproteins / Q000097:blood / Q000187:drug effects; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D004334:Drug Administration Schedule; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D017698:Postmenopause; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004966:Estrogens, Conjugated (USP); D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D017258:Medroxyprogesterone Acetate